In December 2004, the Institute proposed that the review of NICE Technology Appraisal Guidance no. 23, on the use of temozolamide for recurrent malignant glioma should be delayed pending availability of results from the MRC trial BR12.

The comments received by the Institute during consultation agreed with this proposal.

After consideration of all of the comments, the Institute’s Guidance Executive has decided to proceed with the proposal.

The Institute plans to consult on a draft scope for the review in 2006.  The exact timing will depend on the progression of the trial.